SELLAS Life Sciences Group - Licensed Asset Aims To Prolong Survival in Cancer Patients - Dr. Angelos Stergiou, President and CEO of SELLAS Life Sciences Group 00:00:00

Share On Facebook Share On Twitter

Dr. Angelos Stergiou, President and CEO of SELLAS Life Sciences Group, a late-stage clinical biopharmaceutical company discusses their Phase 3 lead asset, Galinpepimut-S (GPS) a novel immunotherapy

Recent Videos